USD 285,000 A Dose: First Drug For Rare Alexander Disease Gets FDA Nod

A first-of-its-kind treatment for Alexander disease, an ultra-rare and progressive neurological disorder, has won US FDA approval at a price of USD 285,000 a dose, raising hopes for families worldwide while also putting the spotlight on the affordability and accessibility of such therapies for rare-disease patients.

The therapy is designed to tackle the biological process driving the disease rather than merely managing its symptoms.

“For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses,” said Emily Freilich, MD, director, Division of Neurology I, FDA’s Center for Drug Evaluation and Research. The approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease, said Freilich, according to a news agency.

Alexander disease is caused by mutations in the GFAP gene, resulting in abnormal production and accumulation of glial fibrillary acidic protein in the brain's supportive cells. The progressive damage can affect movement, development and other neurological functions. Depending on the age at which it begins, patients may develop seizures, loss of developmental milestones, difficulty walking, muscle weakness and problems involving swallowing and other essential functions.

The disease is exceptionally uncommon, estimated to affect roughly one in one to three million people worldwide. Its rarity itself can make diagnosis difficult, particularly in settings where access to specialised neurological and genetic testing is limited.

Zanvastro represents a shift in approach because it does not merely attempt to control the consequences of the disease. It is an RNA-targeted antisense oligonucleotide designed to reduce production of abnormal GFAP protein before it accumulates.

The drug is administered by injection into the spinal canal once every three months by a trained healthcare professional.

The FDA approval was based on a clinical trial involving patients from childhood to adulthood. Among patients aged five years and older who already had measurable walking difficulties, those receiving Zanvastro demonstrated a significantly better walking speed at 61 weeks than those who did not receive treatment.

For younger children aged two to four years, walking speed was considered an unreliable measure because of normal developmental differences.

Additional trial data presented this year also indicated benefits across several symptom domains, while plasma GFAP levels were reduced by 33.6% compared with controls in an exploratory analysis.

But the breakthrough comes with an important caveat for India: availability and affordability could determine how much of this scientific progress reaches Indian patients.

The US list price announced by Ionis is USD 285,000 per dose, with the treatment administered quarterly. That translates into an extremely high treatment cost even before accounting for taxes, importation, specialist administration and other medical expenses.

For India's rare-disease patients, such pricing could make access a major concern unless the medicine eventually becomes available through mechanisms such as manufacturer-supported access programmes, insurance or government assistance, and potentially more affordable pricing arrangements.

The FDA has also flagged safety concerns. Common side effects include vomiting, back pain, cough, headache and post-lumbar-puncture syndrome. Aseptic meningitis has also been reported in treated patients.

Still, the approval marks a significant change for a disease for which families have historically had little beyond supportive treatment.

The development also highlights a larger issue for India: as precision medicines and gene- or RNA-targeted therapies emerge for rare diseases, the challenge is increasingly moving beyond discovering treatments to ensuring that patients in countries such as India can actually receive them.

For Indian families dealing with an unexplained progressive neurological disorder, therefore, the Zanvastro approval offers hope — but the next question is likely to be when that hope can translate into an accessible treatment option at home.